These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 19193551)
1. Five families living with hereditary breast and ovarian cancer risk. Norris J; Spelic SS; Snyder C; Tinley S Clin J Oncol Nurs; 2009 Feb; 13(1):73-80. PubMed ID: 19193551 [TBL] [Abstract][Full Text] [Related]
2. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844 [TBL] [Abstract][Full Text] [Related]
3. Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups. Mellon S; Berry-Bobovski L; Gold R; Levin N; Tainsky MA Psychooncology; 2006 Mar; 15(3):193-208. PubMed ID: 16100704 [TBL] [Abstract][Full Text] [Related]
4. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous interdisciplinary counseling in German breast/ovarian cancer families: first experiences with patient perceptions, surveillance behavior and acceptance of genetic testing. Hofferbert S; Worringen U; Backe J; Rückert EM; White K; Faller H; Grimm T; Caffier H; Chang-Claude J; Weber BH Genet Couns; 2000; 11(2):127-46. PubMed ID: 10893664 [TBL] [Abstract][Full Text] [Related]
6. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. Hallowell N; Ardern-Jones A; Eeles R; Foster C; Lucassen A; Moynihan C; Watson M Clin Genet; 2005 Jun; 67(6):492-502. PubMed ID: 15857416 [TBL] [Abstract][Full Text] [Related]
7. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347 [TBL] [Abstract][Full Text] [Related]
9. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076 [TBL] [Abstract][Full Text] [Related]
11. Beating the biological clock: the compressed family life cycle of young women with BRCA gene alterations. Werner-Lin A Soc Work Health Care; 2008; 47(4):416-37. PubMed ID: 19042494 [TBL] [Abstract][Full Text] [Related]
12. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24. Werner-Lin A; Hoskins LM; Doyle MH; Greene MH Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552 [TBL] [Abstract][Full Text] [Related]
13. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737 [TBL] [Abstract][Full Text] [Related]
14. We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC). Kenen R; Arden-Jones A; Eeles R Psychooncology; 2004 May; 13(5):335-45. PubMed ID: 15133774 [TBL] [Abstract][Full Text] [Related]
15. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer. Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the needs and concerns of partners of women at high risk of developing breast/ovarian cancer. Mireskandari S; Meiser B; Sherman K; Warner BJ; Andrews L; Tucker KM Psychooncology; 2006 Feb; 15(2):96-108. PubMed ID: 15880639 [TBL] [Abstract][Full Text] [Related]
17. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048 [TBL] [Abstract][Full Text] [Related]
18. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. Bradbury AR; Dignam JJ; Ibe CN; Auh SL; Hlubocky FJ; Cummings SA; White M; Olopade OI; Daugherty CK J Clin Oncol; 2007 Aug; 25(24):3705-11. PubMed ID: 17704419 [TBL] [Abstract][Full Text] [Related]
19. Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling. Decruyenaere M; Evers-Kiebooms G; Denayer L; Welkenhuysen M; Claes E; Legius E; Demyttenaere K Eur J Hum Genet; 2000 Feb; 8(2):130-6. PubMed ID: 10757645 [TBL] [Abstract][Full Text] [Related]
20. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Forman AD; Hall MJ Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]